Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice the first physiological effects of Mounjaro within 24 to 72 hours of their initial 2.5mg injection, though meaningful weight change takes weeks rather than days. The 2.5mg starting dose is designed to let your body adjust, not to drive rapid results — so what you feel early on and what the medicine is actually doing are two different things. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber must assess your suitability before it can be dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide reaches peak blood concentration roughly 24 hours after a subcutaneous injection, so the medicine is circulating well before most people notice anything. At 2.5mg, appetite suppression is often mild. Some people report feeling slightly fuller than usual after a meal; others feel almost nothing different. Neither response tells you whether the treatment will work for you at higher doses.
The job of the first pen is adjustment. Tirzepatide activates both GIP and GLP-1 receptors, which slows gastric emptying and affects appetite signals in the brain. At lower concentrations those effects are present but gentle. Taking your first dose correctly (right technique, right site, right time of week) gives the medicine the best possible starting conditions, but it won't accelerate what is fundamentally a gradual biological process.
If you feel nausea, mild bloating or some fatigue in the first day or two, that is the GI profile typical of GLP-1 class medicines, reported in the Mounjaro clinical trials and described in detail on the NHS tirzepatide medicines page. It usually settles within a week. It is not a sign the dose is too strong; it is the system doing exactly what it is supposed to do at low concentration.
This is the window where the decision about whether treatment is working becomes real. Drug levels accumulate weekly, and by around week four (when many patients move to 5mg) the appetite-suppressing effect becomes more pronounced. Meals feel smaller. The pull toward snacking weakens. The timeline after that first injection is not linear: each dose builds on the last.
Clinical trial data from SURMOUNT-1 (2,539 adults, 72 weeks) showed average body-weight reductions of around 20–21% at the highest dose, but those results accumulated across the full titration schedule, not in a single early step. The NICE technology appraisal for tirzepatide (TA1026) notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing treatment should be reviewed. Six months is the benchmark, not six days.
If you're weighing up how soon Mounjaro works compared with what you might expect from 5mg, the 5mg timeline page covers that shift in detail. There is a meaningful difference in how people feel once the dose increases.
Here is the thing that surprises most people: the first four weeks are not the test. The titration schedule exists because the body needs time to reach a therapeutic steady state, and because starting too fast almost always means worse side effects and early discontinuation. A patient who stops at week three because they have not lost weight yet is making a decision on incomplete information.
Timing the first injection sensibly matters too. If your prescription arrives on a Friday and you have a big family weekend ahead, waiting until Monday morning gives you a quieter first 48 hours to notice how your body responds. Similarly, patients who receive their pen just before a bank holiday sometimes find it easier to start the following week. There is no clinical reason to delay unnecessarily, but starting when you can pay attention is reasonable.
Understanding when to take your first dose of Mounjaro in the context of your week is a practical detail our prescribers discuss regularly. Some context on cost over the titration period is worth having early too; the Mounjaro cost page lays out what a private prescription realistically involves across the full schedule.
For people who have type 2 diabetes as well as a weight-management goal, tirzepatide's effect on blood glucose tends to appear earlier than significant weight loss. The GLP-1 and GIP mechanisms influence insulin secretion and glucagon suppression relatively quickly, which is why blood sugar readings can shift within the first one to two weeks for some patients. If that's relevant to your situation, the 2.5mg and blood sugar page covers what to watch for without setting expectations for weight change on the same timeline.
Weight loss and glucose improvement are related but independent effects. A patient might see their fasting glucose improve before their clothes feel looser. That is not treatment failing; it is the two mechanisms working at different speeds. Both are part of why Mounjaro carries its licensed indication for weight management alongside type 2 diabetes.
Our clinical team reviews each consultation individually, including dose-progress checks as treatment continues. If you have questions about how the medicine fits your specific circumstances, starting a free consultation is the right first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.